Temporal range: 49.5–0Ma Eocene - recent
Ginkgo (Ginkgo biloba; in Chinese, Korean and Japanese: 銀杏, pinyin romanization: yín xìng, Revised romanization: "eun haeng", Hepburn romanization: ichō or ginnan, Vietnamese: bạch quả), also spelled gingko and also known as the maidenhair tree, is a unique species of tree with no living relatives. The ginkgo is a living fossil, recognisably similar to fossils dating back 270 million years. Native to China, the tree is widely cultivated and was introduced early to human history. It has various uses in traditional medicine and as a source of food.
- 1 Description
- 2 Branches
- 3 Leaves
- 4 Reproduction
- 5 Distribution and habitat
- 6 Taxonomy and naming
- 7 Etymology
- 8 Palaeontology
- 9 Cultivation and uses
- 10 Hiroshima
- 11 Culinary use
- 12 Potential medicinal uses
- 13 Side effects
- 14 Allergic precautions and contraindications to use
- 15 Review of chemicals in G. biloba
- 16 See also
- 17 References
- 18 Sources
- 19 External links
Ginkgos are large trees, normally reaching a height of 20–35 m (66–115 feet), with some specimens in China being over 50 m (164 feet). The tree has an angular crown and long, somewhat erratic branches, and is usually deep rooted and resistant to wind and snow damage. Young trees are often tall and slender, and sparsely branched; the crown becomes broader as the tree ages. During autumn, the leaves turn a bright yellow, then fall, sometimes within a short space of time (one to 15 days). A combination of resistance to disease, insect-resistant wood and the ability to form aerial roots and sprouts makes ginkgos long-lived, with some specimens claimed to be more than 2,500 years old.
Ginkgo is a relatively shade-intolerant species that (at least in cultivation) grows best in environments that are well-watered and well-drained. The species shows a preference for disturbed sites; in the "semiwild" stands at Tian Mu Shan, many specimens are found along stream banks, rocky slopes, and cliff edges. Accordingly, ginkgo retains a prodigious capacity for vegetative growth. It is capable of sprouting from embedded buds near the base of the trunk (lignotubers, or basal chi chi) in response to disturbances, such as soil erosion. Old individuals are also capable of producing aerial roots on the undersides of large branches in response to disturbances such as crown damage; these roots can lead to successful clonal reproduction upon contacting the soil. These strategies are evidently important in the persistence of ginkgo; in a survey of the "semiwild" stands remaining in Tianmushan, 40% of the specimens surveyed were multistemmed, and few saplings were present.
Ginkgo branches grow in length by growth of shoots with regularly spaced leaves, as seen on most trees. From the axils of these leaves, "spur shoots" (also known as short shoots) develop on second-year growth. Short shoots have very short internodes (so they may grow only one or two centimeters in several years) and their leaves are usually unlobed. They are short and knobby, and are arranged regularly on the branches except on first-year growth. Because of the short internodes, leaves appear to be clustered at the tips of short shoots, and reproductive structures are formed only on them (see pictures below - seeds and leaves are visible on short shoots). In ginkgos, as in other plants that possess them, short shoots allow the formation of new leaves in the older parts of the crown. After a number of years, a short shoot may change into a long (ordinary) shoot, or vice versa.
The leaves are unique among seed plants, being fan-shaped with veins radiating out into the leaf blade, sometimes bifurcating (splitting), but never anastomosing to form a network. Two veins enter the leaf blade at the base and fork repeatedly in two; this is known as dichotomous venation. The leaves are usually 5–10 cm (2–4 in), but sometimes up to 15 cm (6 in) long. The old popular name "maidenhair tree" is because the leaves resemble some of the pinnae of the maidenhair fern, Adiantum capillus-veneris. Ginkgos are prized for their autumn foliage, which is a deep saffron yellow.
Leaves of long shoots are usually notched or lobed, but only from the outer surface, between the veins. They are borne both on the more rapidly growing branch tips, where they are alternate and spaced out, and also on the short, stubby spur shoots, where they are clustered at the tips.
Ginkgos are dioecious, with separate sexes, some trees being female and others being male. Male plants produce small pollen cones with sporophylls, each bearing two microsporangia spirally arranged around a central axis.
Female plants do not produce cones. Two ovules are formed at the end of a stalk, and after pollination, one or both develop into seeds. The seed is 1.5–2 cm long. Its fleshy outer layer (the sarcotesta) is light yellow-brown, soft, and fruit-like. It is attractive in appearance, but contains butyric acid (also known as butanoic acid) and smells like rancid butter or vomit when fallen. Beneath the sarcotesta is the hard sclerotesta (the "shell" of the seed) and a papery endotesta, with the nucellus surrounding the female gametophyte at the center.
The fertilization of ginkgo seeds occurs via motile sperm, as in cycads, ferns, mosses and algae. The sperm are large (about 70–90 micrometres) and are similar to the sperm of cycads, which are slightly larger. Ginkgo sperm were first discovered by the Japanese botanist Sakugoro Hirase in 1896. The sperm have a complex multi-layered structure, which is a continuous belt of basal bodies that form the base of several thousand flagella which actually have a cilia-like motion. The flagella/cilia apparatus pulls the body of the sperm forwards. The sperm have only a tiny distance to travel to the archegonia, of which there are usually two or three. Two sperm are produced, one of which successfully fertilizes the ovule. Although it is widely held that fertilization of ginkgo seeds occurs just before or after they fall in early autumn, embryos ordinarily occur in seeds just before and after they drop from the tree.
Ginkgo tree in autumn
Distribution and habitat
Although Ginkgo biloba and other species of the genus were once widespread throughout the world, its range shrank until by two million years ago, it was restricted to a small area of China. For centuries, it was thought to be extinct in the wild, but is now known to grow in at least two small areas in Zhejiang province in eastern China, in the Tianmushan Reserve. However, recent studies indicate high genetic uniformity among ginkgo trees from these areas, arguing against a natural origin of these populations and suggesting the ginkgo trees in these areas may have been planted and preserved by Chinese monks over a period of about 1,000 years. This study demonstrates a greater genetic diversity in Southwestern China populations, supporting glacial refugia in mountains surrounding eastern Qinghai-Tibet Plateau, where several old-grow, candidates to wild populations have been reported. Whether native ginkgo populations still exist has not been demonstrated unequivocally, but evidence grows favouring these Southwestern populations as wild, from genetic data but also from history of those territories, with bigger Ginkgo biloba trees being older than surrounding human settlements.
Where it occurs in the wild, it is found infrequently in deciduous forests and valleys on acidic loess (i.e. fine, silty soil) with good drainage. The soil it inhabits is typically in the pH range of 5.0 to 5.5.
In many areas of China, it has been long cultivated, and it is common in the southern third of the country. It has also been commonly cultivated in North America for over 200 years and in Europe for close to 300, but during that time, it has never become significantly naturalized.
Taxonomy and naming
The species was initially described by Linnaeus in 1771, the specific epithet biloba derived from the Latin bis, 'two' and loba, 'lobed', referring to the shape of the leaves. Two names for the species recognise the botanist Richard Salisbury, a placement by Nelson as Pterophyllus salisburiensis and the earlier Salisburia adiantifolia proposed by James Edward Smith. The epithet of the latter may have been intended to denote a characteristic resembling Adiantum, the genus of maidenhair ferns.
The relationship of ginkgo to other plant groups remains uncertain. It has been placed loosely in the divisions Spermatophyta and Pinophyta, but no consensus has been reached. Since its seeds are not protected by an ovary wall, it can morphologically be considered a gymnosperm. The apricot-like structures produced by female ginkgo trees are technically not fruits, but are seeds that have a shell consisting of a soft and fleshy section (the sarcotesta), and a hard section (the sclerotesta).
The ginkgo is classified in its own division, the Ginkgophyta, comprising the single class Ginkgoopsida, order Ginkgoales, family Ginkgoaceae, genus Ginkgo and is the only extant species within this group. It is one of the best-known examples of a living fossil, because Ginkgoales other than G. biloba are not known from the fossil record after the Pliocene.
The older Chinese name for this plant is 銀果, meaning "silver fruit", pronounced yínguǒ in Mandarin or Ngan-gwo in Cantonese. The most usual names today are 白果 (bái guǒ), meaning "white fruit", and 銀杏 (yínxìng), meaning "silver apricot". The former name was borrowed directly in Vietnamese as bạch quả. The latter name was borrowed in Japanese ぎんなん (ginnan) and Korean 은행 (eunhaeng), when the tree itself was introduced from China.
The scientific name Ginkgo is the result of a spelling error that occurred three centuries ago. Kanji typically have multiple pronunciations in Japanese, and the characters 銀杏 used for ginnan can also be pronounced ginkyō. Engelbert Kaempfer, the first Westerner to investigate the species in 1690, wrote down this pronunciation in his notes he later used for the Amoenitates Exoticae (1712) with the "awkward" spelling "ginkgo". This appears to be a simple error of Kaempfer, taking his spelling of other Japanese words containing the syllable "kyō" into account, a more precise romanization following his writing habits would have been "ginkio" or "ginkjo". Linné, who relied on Kaempfer when dealing with Japanese plants adopted the spelling given in Kaempfer's "Flora Japanica" (Amoenitates Exoticae, p. 811).
The ginkgo is a living fossil, with fossils recognisably related to modern ginkgo from the Permian, dating back 270 million years. The most plausible ancestral group for the order Ginkgoales is the Pteridospermatophyta, also known as the "seed ferns", specifically the order Peltaspermales. The closest living relatives of the clade are the cycads, which share with the extant G. biloba the characteristic of motile sperm. Fossils attributable to the genus Ginkgo first appeared in the Early Jurassic, and the genus diversified and spread throughout Laurasia during the middle Jurassic and Early Cretaceous. It declined in diversity as the Cretaceous progressed, and by the Paleocene, Ginkgo adiantoides was the only Ginkgo species left in the Northern Hemisphere, while a markedly different (and poorly documented) form persisted in the Southern Hemisphere. At the end of the Pliocene, Ginkgo fossils disappeared from the fossil record everywhere except in a small area of central China, where the modern species survived. It is doubtful whether the Northern Hemisphere fossil species of Ginkgo can be reliably distinguished. Given the slow pace of evolution and morphological similarity between members of the genus, there may have been only one or two species existing in the Northern Hemisphere through the entirety of the Cenozoic: present-day G. biloba (including G. adiantoides) and G. gardneri from the Paleocene of Scotland.
At least morphologically, G. gardneri and the Southern Hemisphere species are the only known post-Jurassic taxa that can be unequivocally recognised. The remainder may have been ecotypes or subspecies. The implications would be that G. biloba had occurred over an extremely wide range, had remarkable genetic flexibility and, though evolving genetically, never showed much speciation. While it may seem improbable that a species may exist as a contiguous entity for many millions of years, many of the ginkgo's life-history parameters fit. These are: extreme longevity; slow reproduction rate; (in Cenozoic and later times) a wide, apparently contiguous, but steadily contracting distribution coupled with, as far as can be demonstrated from the fossil record, extreme ecological conservatism (restriction to disturbed streamside environments).
Modern-day G. biloba grows best in environments that are well-watered and drained, and the extremely similar fossil Ginkgo favored similar environments: the sediment record at the majority of fossil Ginkgo localities indicates it grew primarily in disturbed environments along streams and levees. Ginkgo, therefore, presents an "ecological paradox" because while it possesses some favorable traits for living in disturbed environments (clonal reproduction) many of its other life-history traits (slow growth, large seed size, late reproductive maturity) are the opposite of those exhibited by modern plants that thrive in disturbed settings.
Given the slow rate of evolution of the genus, Ginkgo possibly represents a preangiosperm strategy for survival in disturbed streamside environments. Ginkgo evolved in an era before flowering plants, when ferns, cycads, and cycadeoids dominated disturbed streamside environments, forming low, open, shrubby canopies. Ginkgo's large seeds and habit of "bolting" - growing to a height of 10 m before elongating its side branches - may be adaptions to such an environment. Because diversity in the genus Ginkgo drops through the Cretaceous (along with that of ferns, cycads, and cycadeoids) at the same time the flowering plants were on the rise, the notion that flowering plants with better adaptations to disturbance displaced Ginkgo and its associates over time is supported.
Ginkgo has been used for classifying plants with leaves that have more than four veins per segment, while Baiera for those with fewer than four veins per segment. Sphenobaiera has been used to classify plants with a broadly wedge-shaped leaf that lacks a distinct leaf stem. Trichopitys is distinguished by having multiple-forked leaves with cylindrical (not flattened), thread-like ultimate divisions; it is one of the earliest fossils ascribed to the Ginkgophyta.
Extant Ginkgo biloba
Cultivation and uses
Ginkgo has long been cultivated in China; some planted trees at temples are believed to be over 1,500 years old. The first record of Europeans encountering it is in 1690 in Japanese temple gardens, where the tree was seen by the German botanist Engelbert Kaempfer. Because of its status in Buddhism and Confucianism, the ginkgo is also widely planted in Korea and parts of Japan; in both areas, some naturalization has occurred, with ginkgos seeding into natural forests.
In some areas, most intentionally planted ginkgos are male cultivars grafted onto plants propagated from seed, because the male trees will not produce the malodorous seeds. The popular cultivar "Autumn Gold" is a clone of a male plant.
The disadvantage of male ginkgo biloba trees is that they are highly allergenic. Male ginkgo biloba trees have an OPALS allergy scale rating of 7 (out of 10), while female trees, which can produce no pollen, have an OPALS allergy scale rating of 2.
Female cultivars include "Liberty Splendor", "Santa Cruz", and "Golden Girl", so named because of the striking yellow color of its leaves in the fall.
Ginkgos adapt well to the urban environment, tolerating pollution and confined soil spaces. They rarely suffer disease problems, even in urban conditions, and are attacked by few insects. For this reason, and for their general beauty, ginkgos are excellent urban and shade trees, and are widely planted along many streets.
The ginkgo leaf is the symbol of the Urasenke school of Japanese tea ceremony. The tree is the national tree of China, and is the official tree of the Japanese capital of Tokyo, and the symbol of Tokyo is a ginkgo leaf.
Extreme examples of the ginkgo's tenacity may be seen in Hiroshima, Japan, where six trees growing between 1–2 km from the 1945 atom bomb explosion were among the few living things in the area to survive the blast. While almost all other plants (and animals) in the area were destroyed, the ginkgos, though charred, survived and were soon healthy again. The trees are alive to this day.
The nut-like gametophytes inside the seeds are particularly esteemed in Asia, and are a traditional Chinese food. Ginkgo nuts are used in congee, and are often served at special occasions such as weddings and the Chinese New Year (as part of the vegetarian dish called Buddha's delight). In Chinese culture, they are believed to have health benefits; some also consider them to have aphrodisiac qualities. Japanese cooks add ginkgo seeds (called ginnan) to dishes such as chawanmushi, and cooked seeds are often eaten along with other dishes.
When eaten in large quantities or over a long period, especially by children the gametophyte (meat) of the seed can cause poisoning by 4'-O-methylpyridoxine (MPN). MPN is heat stable and not destroyed by cooking. Studies have demonstrated the convulsions caused by MPN can be prevented or terminated with pyridoxine.
Some people are sensitive to the chemicals in the sarcotesta, the outer fleshy coating. These people should handle the seeds with care when preparing the seeds for consumption, wearing disposable gloves. The symptoms are allergic contact dermatitis or blisters similar to that caused by contact with poison ivy. However, seeds with the fleshy coating removed are mostly[clarification needed][quantify] safe to handle.
Potential medicinal uses
Extracts of ginkgo leaves contain flavonoid glycosides (myricetin and quercetin) and terpenoids (ginkgolides, bilobalides) and have been used pharmaceutically. These extracts are shown to exhibit reversible, nonselective monoamine oxidase inhibition, as well as inhibition of reuptake at the serotonin, dopamine, and norepinephrine transporters, with all but the norepinephrine reuptake inhibition fading in chronic exposure. Ginkgo extract has in addition been found to act as a selective 5-HT1A receptor agonist in vivo. Ginkgo supplements are usually taken in the range of 40–200 mg per day. In 2010, a meta-analysis of clinical trials has shown Ginkgo to be moderately effective in improving cognition in dementia patients but not preventing the onset of Alzheimer's disease in people without dementia. In research not yet confirmed by clinical or governmental agencies, ginkgo may have some efficacy in treating the symptoms of schizophrenia.
As a memory and concentration enhancement
Ginkgo is believed to have nootropic properties, and is mainly used as memory and concentration enhancer, and antivertigo agent. However, studies differ about its efficacy. The largest and longest independent clinical trial to assess Ginkgo biloba published the finding in 2008 that the supplement does not reduce incidence of all-cause dementia or Alzheimer's disease in adults 75 years or older who had normal cognition or mild cognitive impairment when given a twice-daily dose of 120 mg extract of G. biloba. However, a similar trial published in December 2010 concluded the same extract formulation of G. biloba (EGb 761), when given as a single 240-mg daily dose, "was found significantly superior to placebo in the treatment of patients with dementia with neuropsychiatric symptoms" in a trial with 410 out-patients.
According to some studies, Ginkgo can significantly improve attention in healthy individuals. In one such study, the effect was almost immediate and reaches its peak 2.5 hours after the intake.
Nonetheless, a meta-analysis in 2012 reported zero effect sizes for the impact of Ginkgo biloba on memory, attention and problem-solving in healthy individuals.
Ginkgo has been studied as a possible treatment for Alzheimer's disease. Preliminary studies were encouraging, but the current understanding is that Ginkgo is not an effective treatment or preventative for Alzheimer's. Research began with positive preclinical results in mice, and a 2006 study found 160 mg of ginkgo extract to be as effective as a daily 5-mg dose of the cholinesterase inhibitor donepezil in human subjects. A 2008 randomized controlled clinical trial found ginkgo ineffective at treating dementia in humans at a daily dose of 120 mg. A similar trial published in 2010, however, found ginkgo effective at treating mild to moderate dementia at the higher single dose of 240 mg daily. Another randomized controlled trial, published in 2009, found no benefit from ginkgo in preventing cognitive decline or dementia when given at a dose of 120 mg twice daily. A similar study reported in 2012 concluded the long-term use of Ginkgo biloba extract does not affect progression to Alzheimer's disease. A recent meta-analysis of 9 studies of ginkgo for use in the treatment of dementia concluded it was more effective than placebo, although, like other dementia drugs, the clinical significance of these moderate effects was difficult to quantify. An editorial in The Lancet concluded ginkgo biloba does not prevent dementia in elderly individuals with or without memory complaints or cognitive impairment and is not effective for prevention of Alzheimer's disease.
In other symptoms
Of the many conflicting results from basic research, ginkgo extract may have three effects on the human body: improvement in blood flow to most tissues and organs, protection against oxidative cell damage from free radicals, and blockage of many of the effects of platelet-activating factor (platelet aggregation, blood clotting) that have been related to the development of a number of cardiovascular, renal, respiratory and central nervous system disorders. Ginkgolides, especially ginkgolide B, are potent antagonists against platelet-activating factor, and thus may be useful in protection and prevention of thrombus, endotoxic shock, and from myocardial ischemia.
The World Health Organization reported possible medicinal uses of Ginkgo biloba shown in preliminary clinical research include treatment of the effects of mild to moderate cerebrovascular insufficiency and of peripheral arterial occlusive diseases. Cerebrovascular insufficiency, i.e. insufficient blood flow to the brain, may manifest itself as memory deficit, disturbed concentration or headaches. Other preliminary studies failed to show any effect of ginkgo on cognitive function in patients with multiple sclerosis.
Ginkgo may have undesirable effects, especially for individuals with blood circulation disorders and those taking anticoagulants such as aspirin or warfarin, although recent studies have found ginkgo has little or no effect on the anticoagulant properties or pharmacodynamics of warfarin in healthy subjects. Ginkgo inhibits monoamine oxidase, so people who are taking certain types of antidepressants (such as monoamine oxidase inhibitors and selective serotonin reuptake inhibitors), as well as pregnant women, may experience side effects.
Ginkgo biloba preparations have shown some carcinogenic effects in animal models, but they are not classified as human carcinogens. The lowest observed dosages that caused adverse effect in these animal studies were at 100 mg/kg, and thus dosages that are impossible to reach by the consumption of Ginkgo Biloba preparations. Aside of possible complications in combination with anti-coagulant drugs, standardized preparations of Ginkgo biloba are safe, and side effects are rare.
Allergic precautions and contraindications to use
Some authors claim that Ginkgo biloba extracts, which are co-administered with anticoagulant drugs such as warfarin or coumadin, increase the risk for bleeding due to their assumed antiplatelet activity. Concerns that standardized Ginkgo biloba preparations (GBE) significantly impact haemostasis or adversely affect the safety of anticoagulant drugs are however not supported by current medical literature.
The presence of amentoflavone in G. biloba leaves would indicate a potential for interactions with many medications through the strong inhibition of CYP3A4 and CYP2C9; however, no empirical evidence supports this. Further, at recommended doses, studies have shown, "[m]ultiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers." The concentration of amentoflavone found even in commercial ginkgo extracts possibly is too low to be pharmacologically active.
Ginkgo biloba leaves and sarcotesta also contain ginkgolic acids, which are highly allergenic, long-chain alkylphenols such as bilobol or adipostatin A (bilobol is a substance related to anacardic acid from cashew nut shells and urushiols present in poison ivy and other Toxicodendron spp.) Individuals with a history of strong allergic reactions to poison ivy, mangoes, cashews and other alkylphenol-producing plants are more likely to experience allergic reaction when consuming non-standardized ginkgo-containing preparations, combinations, or extracts thereof. The level of these allergens in standardized pharmaceutical preparations from Ginkgo biloba was restricted to 5 ppm by the Commission E of the former Federal German Health Authority.
Review of chemicals in G. biloba
The plant also contains biflavones Important constituents present in the medicinally used leaves are the terpene trilactones, i.e., ginkgolides A, B, C, J and bilobalide, many flavonol glycosides, biflavones, proanthocyanidins, alkylphenols, simple phenolic acids, 6-hydroxykynurenic acid, 4-O-methylpyridoxine and polyprenols.
- André Michaux, introduced the ginkgo to North America
- Ginkgo/Wanapum State Park in central Washington, USA
- List of edible seeds
- Mustoe, G.E. (2002). "Eocene Ginkgo leaf fossils from the Pacific Northwest". Canadian Journal of Botany 80 (10): 1078–1087. doi:10.1139/b02-097.
- Sun (1998). 'Ginkgo biloba'. 2006. IUCN Red List of Threatened Species. IUCN 2006. www.iucnredlist.org. Retrieved on 11 May 2006. Listed as Endangered (EN B1+2c v2.3)
- "Gingko". Dictionary.com. Retrieved 28 March 2013.
- Royer et al., pp. 86-87
- Ginkgoales: More on Morphology
- Raven, Peter H.; Ray F. Evert; Susan E. Eichhorn (2005). Biology of Plants (7th ed.). New York: W. H. Freeman and Company. pp. 429–430. ISBN 0-7167-1007-2.
- Plotnik, Arthur (2000). The Urban Tree Book: An Uncommon Field Guide for City and Town (1st ed.). New York: Three Rivers Press. p. 202. ISBN 0-8129-3103-3.
- Laboratory IX -- Ginkgo, Cordaites, and the Conifers
- Vanbeek A. Vanbeek (2000). Ginkgo Biloba (Medicinal and Aromatic Plants: Industrial Profiles). CRC Press. p. 37. ISBN 90-5702-488-8.
- History of Discovery of Spermatozoids In Ginkgo biloba and Cycas revoluta
- Holt, B. F.; Rothwell, G. W. (1997). "Is Ginkgo biloba (Ginkgoaceae) Really an Oviparous Plant?". American Journal of Botany 84 (6): 870–872. doi:10.2307/2445823. JSTOR 2445823.
- Shen, L; Chen, X-Y; Zhang, X; Li, Y-Y; Fu, C-X; Qiu, Y-X (2004). "Genetic variation of Ginkgo biloba L. (Ginkgoaceae) based on cpDNA PCR-RFLPs: inference of glacial refugia". Heredity 94 (4): 396–401. doi:10.1038/sj.hdy.6800616. PMID 15536482.
- Tang, CQ; al, et (2012). "Evidence for the persistence of wild Ginkgo biloba (Ginkgoaceae) populations in the Dalou Mountains, southwestern China". American Journal of Botany 99 (8): 1408–1414. doi:10.3732/ajb.1200168.
- Fu, Liguo; Li, Nan; Mill, Robert R. (1999). "Ginkgo biloba". In Wu, Z. Y.; Raven, P.H.; Hong, D.Y. Flora of China 4. Beijing: Science Press; St. Louis: Missouri Botanical Garden Press. p. 8. Retrieved 31 March 2008.
- Whetstone, R. David (2006). "Ginkgo biloba". In Flora of North America Editorial Committee, eds. 1993+. Flora of North America 2. New York & Oxford: Oxford University Press.
- Simpson DP (1979). Cassell's Latin Dictionary (5 ed.). London: Cassell Ltd. p. 883. ISBN 0-304-52257-0.
- Chandler, Brian (2000). "Ginkgo - origins". Ginkgo pages. Retrieved 22 November 2010.
- Zhou, Zhiyan; Zheng, Shaolin (2003). "Palaeobiology: The missing link in Ginkgo evolution". Nature 423 (6942): 821–2. doi:10.1038/423821a. PMID 12815417.
- Julie Jalalpour, Matt Malkin, Peter Poon, Liz Rehrmann, Jerry Yu (1997). "Ginkgoales: Fossil Record". University of California, Berkeley. Retrieved 3 June 2008.
- Wolfgang Michel: On Engelbert Kaempfer’s "Ginkgo". Research Notes, 2005/2011
- Royer et al., p.84
- Royer et al., p.85
- Royer et al., p.91
- Royer et al., p.87
- Royer et al., p.92
- Royer et al., p.93
- Approximate reconstructions by B. M. Begović Bego and Z. Zhou, 2010/2011. Source: B.M. Begović Bego, (2011). Nature's Miracle Ginkgo biloba, Book 1, Vols. 1–2, pp. 60–61.
- Ogren, Thomas Leo (2000). Allergy-Free Gardening. Berkeley, California: Ten Speed Press. p. 112. ISBN 1-58008-166-5.
- Gilman, Edward F. and Dennis G. Watson (1993). "Ginkgo biloba 'Autumn Gold'" (PDF). US Forest Service. Retrieved 29 March 2008.
- Boland, Timothy, Laura E. Coit, Marty Hair (2002). Michigan Gardener's Guide. Cool Springs Press. ISBN 1-930604-20-3.
- "Examples of Plants with Insect and Disease Tolerance". SULIS - Sustainable Urban Landscape Information Series. University of Minnesota. Retrieved 29 March 2008.
- D'Cruz, Mark. "Ma-Ke Bonsai Care Guide for Ginkgo biloba". Ma-Ke Bonsai. Retrieved 2013-09-12.
- "A-bombed Ginkgo trees in Hiroshima, Japan", The Ginkgo Pages.
- Ginkgo Seed Poisoning. PEDIATRICS Vol. 109 No. 2 February 2002, pp. 325-327 
- Lepoittevin, J. -P.; Benezra, C.; Asakawa, Y. (1989). "Allergic contact dermatitis to Ginkgo biloba L.: relationship with urushiol". Archives of Dermatological Research 281 (4): 227–30. doi:10.1007/BF00431055. PMID 2774654.
- Schötz, Karl (2004). "Quantiﬁcation of allergenic urushiols in extracts ofGinkgo biloba leaves, in simple one-step extracts and reﬁned manufactured material(EGb 761)". Phytochemical Analysis 15 (1): 1–8. doi:10.1002/pca.733. PMID 14979519.
- Myricetin and quercetin, the flavonoid constituents ofGinkgobiloba extract, greatly reduce oxidative metabolism in both resting and Ca2+-loaded brain neurons. Yasuo Oyama, Paul A. Fuchs, Norihiro Katayama and Katsuhiko Noda, Brain Research, 28 January 1994, Volume 635, Issues 1–2, Pages 125–129, doi:10.1016/0006-8993(94)91431-1
- Fehske, Christian J.; Leuner, Kristina; Müller, Walter E. (2009). "Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment". Pharmacological Research 60 (1): 68–73. doi:10.1016/j.phrs.2009.02.012. PMID 19427589.
- Winter, JC; Timineri, D (Mar 1999). "The discriminative stimulus properties of EGb 761, an extract of Ginkgo biloba.". Pharmacology, Biochemistry, and Behavior 62 (3): 543–7. doi:10.1016/S0091-3057(98)00190-7. PMID 10080249.
- Weinmann, S; Roll, S; Schwarzbach, C; Vauth, C; Willich, SN (2010). "Effects of Ginkgo biloba in dementia: systematic review and meta-analysis". BMC geriatrics 10: 14. doi:10.1186/1471-2318-10-14. PMC 2846949. PMID 20236541.
- Dekosky, S. T.; Williamson, J. D.; Fitzpatrick, A. L.; Kronmal, R. A. et al. (2008). "Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial". JAMA: the Journal of the American Medical Association 300 (19): 2253–62. doi:10.1001/jama.2008.683. PMC 2823569. PMID 19017911.
- Snitz, B. E.; O'Meara, E. S.; Carlson, M. C.; Arnold, A. M. et al. (2009). "Ginkgo biloba for Preventing Cognitive Decline in Older Adults: A Randomized Trial". JAMA: the Journal of the American Medical Association 302 (24): 2663–70. doi:10.1001/jama.2009.1913.
- Zhang, W. F.; Tan, Y. L.; Zhang, X. Y.; Chan, R. C. K.; Wu, H. R.; Zhou, D. F. (2011). "Extract ofGinkgo bilobaTreatment for Tardive Dyskinesia in Schizophrenia". The Journal of Clinical Psychiatry 72 (5): 615–621. doi:10.4088/JCP.09m05125yel. PMID 20868638.
- Zhang, X. Y.; Zhou, D. F.; Cao, L. Y.; Wu, G. Y. (2006). "The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: A double-blind, placebo-controlled trial". Psychopharmacology 188 (1): 12–17. doi:10.1007/s00213-006-0476-2. PMID 16906395.
- Doruk, A.; Uzun, Ö.; Ozşahin, A. (2008). "A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia". International Clinical Psychopharmacology 23 (4): 223–227. doi:10.1097/YIC.0b013e3282fcff2f. PMID 18545061.
- Atmaca, M.; Tezcan, E.; Kuloglu, M.; Ustundag, B.; Kirtas, O. (2005). "The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia". Psychiatry and Clinical Neurosciences 59 (6): 652–656. doi:10.1111/j.1440-1819.2005.01432.x. PMID 16401239.
- Zhang, X. Y.; Zhou, D. F.; Su, J. M.; Zhang, P. Y. (2001). "The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia". Journal of clinical psychopharmacology 21 (1): 85–88. doi:10.1097/00004714-200102000-00015. PMID 11199954.
- Zhang, X. Y.; Zhou, D. F.; Zhang, P. Y.; Wu, G. Y.; Su, J. M.; Cao, L. Y. (2001). "A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia". The Journal of clinical psychiatry 62 (11): 878–883. doi:10.4088/JCP.v62n1107. PMID 11775047.
- Zhou, D.; Zhang, X.; Su, J.; Nan, Z.; Cui, Y.; Liu, J.; Guan, Z.; Zhang, P.; Shen, Y. (1999). "The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia". Chinese medical journal 112 (12): 1093–1096. PMID 11721446.
- Mahadevan, S.; Park, Y. (2007). "Multifaceted Therapeutic Benefits of Ginkgo biloba L.: Chemistry, Efficacy, Safety, and Uses". Journal of Food Science 73 (1): R14–9. doi:10.1111/j.1750-3841.2007.00597.x. PMID 18211362.
- DeKosky, Steven T.; Williamson, Jeff D.; Fitzpatrick, Annette L.; Kronmal, R. A. et al. (2008). "Ginkgo biloba for Prevention of Dementia". The Journal of the American Medical Association 300 (19): 2253–2262. doi:10.1001/jama.2008.683. PMC 2823569. PMID 19017911.
- Rabin, Roni Caryn (November 18, 2008). "Ginkgo biloba Ineffective Against Dementia, Researchers Find". The New York Times. Retrieved 12 October 2009.
- Ihl R; Bachinskaya N; Korczyn AD; Vakhapova V; Tribanek M; Hoerr R; Napryeyenko O (7 December 2010). "Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial". Int J Geriatr Psychiatry: 1186–94. doi:10.1002/gps.2662. PMID 21140383.
- Elsabagh, Sarah; Hartley, David E.; Ali, Osama; Williamson, Elizabeth M.; File, Sandra E. (2005). "Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers". Psychopharmacology 179 (2): 437–46. doi:10.1007/s00213-005-2206-6. PMID 15739076.
- BBC News: Herbal remedies "boost brain power"
- Kennedy, David O.; Scholey, Andrew B.; Wesnes, Keith A. (2000). "The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers". Psychopharmacology 151 (4): 416–23. doi:10.1007/s002130000501. PMID 11026748.
- Laws, Sweetnam and Kondel
- Schneider, L. S. (2012). "Ginkgo and AD: Key negatives and lessons from GuidAge". The Lancet Neurology. doi:10.1016/S1474-4422(12)70212-0.
- Ginkgo Extract Has Multiple Actions on Alzheimer Symptoms Newswise, Retrieved on August 25, 2008.
- Mazza, M.; Capuano, A.; Bria, P.; Mazza, S. (2006). "Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study". European Journal of Neurology 13 (9): 981–5. doi:10.1111/j.1468-1331.2006.01409.x. PMID 16930364.
- McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen J, Warner J (2008). "Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial". Int J Geriatr Psychiatry 23 (12): 1222–30. doi:10.1002/gps.2055. PMID 18537221.
- "Ginkgo 'does not treat dementia'". BBC News. June 16, 2008.
- Vellas, B.; Coley, N.; Ousset, P. J.; Berrut, G.; Dartigues, J. F. O.; Dubois, B.; Grandjean, H. L. N.; Pasquier, F.; Piette, F. O.; Robert, P.; Touchon, J.; Garnier, P.; Mathiex-Fortunet, H. L. N.; Andrieu, S. (2012). "Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): A randomised placebo-controlled trial". The Lancet Neurology 11 (10): 851. doi:10.1016/S1474-4422(12)70206-5.
- Smith, P; MacLennan, K; Darlington, CL (1996). "The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF)". Journal of Ethnopharmacology 50 (3): 131–9. doi:10.1016/0378-8741(96)01379-7. PMID 8691847.
- LU Ding-qiang, CHEN Jun "Pharmacological Activities of Ginkgolides"(School of Biological and Environmental Engineering, Jiangsu University of Science and Techno1ogy, Zhenjiang,Jiangsu 212013, China)http://defeatosteosarcoma.org/category/generalcancerresearch/nutrition-and-cancer/ginkgo-biloba-kaempferol/
- Kang BJ, Lee SJ, Kim MD, Cho MJ (2002). "A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction". Hum Psychopharmacol 17 (6): 279–284. doi:10.1002/hup.409. PMID 12404672.
- Wheatley D (2004). "Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs". Hum Psychopharmacol 19 (8): 545–548. doi:10.1002/hup.627. PMID 15378664.
- "WHO Monographs on Selected Medicinal Plants - Volume 1: Folium Ginkgo". Apps.who.int. Retrieved 2012-08-07.
- DeFeudis FV. Ginkgo biloba extract (egb 761): pharmacological activities and clinical applications. Paris, Elsevier, Editions Scientifiques, 1991:1187
- Kade, F.; Miller, W. (1993). "Dose-dependent effects of Ginkgo biloba extraction on cerebral, mental and physical efficiency: a placebo controlled double blind study". British journal of clinical research 4: 97–103.
- Lovera, J; Bagert, B; Smoot, K; Morris, CD et al. (2007). "2006 ACTRIMS ABSTRACTS: Biomarkers in MS/Basic and clinical issues in multiple sclerosis research, ACTRIMS 11th annual meeting, October 8, 2006, Chicago, Illinois". Multiple Sclerosis 13 (3): 376–85. doi:10.1177/1352458506071213. PMID 17439907.
- Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ (April 2005). "Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects". Br J Clin Pharmacol 59 (4): 425–32. doi:10.1111/j.1365-2125.2005.02322.x. PMC 1884814. PMID 15801937.
- White HL, Scates PW, Cooper BR (1996). "Extracts of Ginkgo biloba leaves inhibit monoamine oxidase". Life Sci. 58 (16): 1315–21. doi:10.1016/0024-3205(96)00097-5. PMID 8614288.
- "MedlinePlus Herbs and Supplements: Ginkgo (Ginkgo biloba L.)". National Institutes of Health. Retrieved 10 April 2008.
- "Ginkgo biloba". University of Maryland Medical Center. Retrieved 10 April 2008.
- Complete Ginkgo information from Drugs.com
- Rider CV, Nyska A, Cora MC, et al. (August 2013). "Toxicity and Carcinogenicity Studies of Ginkgo biloba Extract in Rat and Mouse: Liver, Thyroid, and Nose Are Targets". Toxicol Pathol. doi:10.1177/0192623313501235. PMID 23960164.
- "Toxicology and carcinogenesis studies of Ginkgo biloba extract (CAS No. 90045-36-6) in F344/N rats and B6C3F1/N mice (Gavage studies)". Natl Toxicol Program Tech Rep Ser (578): 1–183. March 2013. PMID 23652021.
- Hoenerhoff MJ, Pandiri AR, Snyder SA, et al. (August 2013). "Hepatocellular carcinomas in B6C3F1 mice treated with Ginkgo biloba extract for two years differ from spontaneous liver tumors in cancer gene mutations and genomic pathways". Toxicol Pathol 41 (6): 826–41. doi:10.1177/0192623312467520. PMID 23262642.
- Bone KM (2008). Mol Nutr Food Res. 52(7):764-71. doi: 10.1002/mnfr.200700098.PMID: 18214851
- Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol. 2003 Dec;23(6):576-81. PubMed: 14624188
- Xian-guo et al. (2000), "High-Performance Liquid Chromatography-Electrospray Ionization-Mass Spectrometry Study of Ginkgolic Acid in the Leaves and Fruits of the Ginkgo Tree (Ginkgo biloba)", Journal of Chromatographic Science 38 (4), pages 169-173. PubMed: 10766484
- Tanaka, A; Arai, Y; Kim, SN; Ham, J; Usuki, T (2011). "Synthesis and biological evaluation of bilobol and adipostatin A". Journal of Asian natural products research 13 (4): 290–6. doi:10.1080/10286020.2011.554828. PMID 21462031.
- Reversed-phase high-performance liquid chromatographic method for the analysis of biflavones in Ginkgo biloba L. extracts. Pietta P, Mauri P and Rava A, Journal of chromatography, 1988, vol. 437, no 2, pages 453-456, INIST:7067692
- Chemical analysis of Ginkgo biloba leaves and extracts. Teris A van Beek, Journal of Chromatography A, 16 August 2002, Volume 967, Issue 1, Pages 21–55, doi:10.1016/S0021-9673(02)00172-3
- Royer, Dana L.; Hickey, Leo J.; Wing, Scott L. (2003). "Ecological conservatism in the 'living fossil' Ginkgo". Paleobiology 29 (1): 84–104. doi:10.1666/0094-8373(2003)029<0084:ECITLF>2.0.CO;2. ISSN 0094-8373.
|Wikispecies has information related to: Ginkgo biloba|
|Wikimedia Commons has media related to Ginkgo biloba.|
- Growing Ginkgoes from seed: by the Ottawa Horticultural Society
- Gymnosperm Database
- University of California Museum of Paleontology
- Ginkgo biloba information (Plants for a Future)
- Ginkgo: MedlinePlus Supplements - U.S. National Library of Medicine
- Ginkgo biloba Overview - University of Maryland Medical Center